Patient characteristics at baseline according to randomization with or without CLO
| . | Standard treatment (arm A) . | CLO + standard treatment (arm B) . |
|---|---|---|
| Total, n | 166 | 168 |
| Age | ||
| Median (range), y | 42 (18-70) | 43 (18-70) |
| 18-40 y, n (%) | 79 (48) | 80 (48) |
| 41-70 y, n (%) | 87 (52) | 88 (52) |
| Performance status, n (%) | ||
| WHO 0 | 69 (42) | 72 (43) |
| WHO 1 | 69 (42) | 67 (40) |
| WHO 2 | 12 (7) | 13 (8) |
| WHO 4 | 1 (1) | — |
| Unknown | 15 (9) | 16 (10) |
| Sex, n (%) | ||
| Male | 96 (58) | 100 (60) |
| Female | 70 (42) | 68 (40) |
| Immunophenotype, n (%) | ||
| B-ALL | 118 (71) | 119 (71) |
| T-ALL | 29 (17) | 28 (17) |
| Mixed phenotype | 5 (3) | 4 (2) |
| T-LBL | 14 (8) | 17 (10) |
| WBC | ||
| Median ×109/L, range | 10.8 (0.5-524) | 11.0 (0.5-540) |
| >30 × 109/L for B-lineage | 33/120 (27) | 30/123 (24) |
| >100x109/L for T-lineage | 6/46 (13) | 2/45 (4) |
| % blast count in BM, median (range) | 88 (0-100) | 88 (0-100) |
| Cytogenetics and/or molecular analysis, n (%) | 7 (4) | 2 (1) |
| Not done/failure | 38/158 (24) | 30/166 (18) |
| t(9;22)/BCR-ABL | 10/156 (6) | 18/164 (11) |
| 11q23 abnormality/MLL fusion | 16/151 (11) | 15/156 (10) |
| Hypodiploidy | 23/151 (15) | 32/156 (21) |
| Complex karyotype | ||
| CNS involvement, n (%) | 5 (3) | 7 (4) |
| Risk group, n (%) | ||
| High risk | 102 (61) | 108 (64) |
| Standard risk | 64 (39) | 60 (36) |
| . | Standard treatment (arm A) . | CLO + standard treatment (arm B) . |
|---|---|---|
| Total, n | 166 | 168 |
| Age | ||
| Median (range), y | 42 (18-70) | 43 (18-70) |
| 18-40 y, n (%) | 79 (48) | 80 (48) |
| 41-70 y, n (%) | 87 (52) | 88 (52) |
| Performance status, n (%) | ||
| WHO 0 | 69 (42) | 72 (43) |
| WHO 1 | 69 (42) | 67 (40) |
| WHO 2 | 12 (7) | 13 (8) |
| WHO 4 | 1 (1) | — |
| Unknown | 15 (9) | 16 (10) |
| Sex, n (%) | ||
| Male | 96 (58) | 100 (60) |
| Female | 70 (42) | 68 (40) |
| Immunophenotype, n (%) | ||
| B-ALL | 118 (71) | 119 (71) |
| T-ALL | 29 (17) | 28 (17) |
| Mixed phenotype | 5 (3) | 4 (2) |
| T-LBL | 14 (8) | 17 (10) |
| WBC | ||
| Median ×109/L, range | 10.8 (0.5-524) | 11.0 (0.5-540) |
| >30 × 109/L for B-lineage | 33/120 (27) | 30/123 (24) |
| >100x109/L for T-lineage | 6/46 (13) | 2/45 (4) |
| % blast count in BM, median (range) | 88 (0-100) | 88 (0-100) |
| Cytogenetics and/or molecular analysis, n (%) | 7 (4) | 2 (1) |
| Not done/failure | 38/158 (24) | 30/166 (18) |
| t(9;22)/BCR-ABL | 10/156 (6) | 18/164 (11) |
| 11q23 abnormality/MLL fusion | 16/151 (11) | 15/156 (10) |
| Hypodiploidy | 23/151 (15) | 32/156 (21) |
| Complex karyotype | ||
| CNS involvement, n (%) | 5 (3) | 7 (4) |
| Risk group, n (%) | ||
| High risk | 102 (61) | 108 (64) |
| Standard risk | 64 (39) | 60 (36) |
LBL, lymphoblastic lymphoma; N, number of patients; WBC, white blood cell count at diagnosis.